Home/Pipeline/Biosimilar Portfolio (e.g., rituximab, bevacizumab)

Biosimilar Portfolio (e.g., rituximab, bevacizumab)

Oncology, Autoimmune Diseases

Phase 3 / RegistrationActive

Key Facts

Indication
Oncology, Autoimmune Diseases
Phase
Phase 3 / Registration
Status
Active
Company

About R-Pharm

R-Pharm is a major, fully-integrated Russian pharmaceutical player with a strategic focus on localizing advanced drug production and developing innovative therapies. The company leverages extensive partnerships with global biopharma leaders to in-license and co-develop products for the Russian and CIS markets, while also advancing its own R&D pipeline. Its significant manufacturing capabilities and government contracts position it as a key domestic supplier, particularly in oncology and critical care. The company's strategy is heavily aligned with Russia's national pharmaceutical import substitution policies.

View full company profile

Other Oncology, Autoimmune Diseases Drugs

DrugCompanyPhase
Biosimilar Pipeline (e.g., Bevacizumab, Trastuzumab)Zydus LifesciencesPhase 3 / Registration